Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDK | P21741 | 4/20 | 0.53 |
| ▸ | BDNF | P23560 | 3/20 | 0.53 |
| ▸ | PTN | P21246 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.43 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.38 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.38 |
| ▸ | CCL2 | P13500 | 1/20 | 0.38 |
| ▸ | CCL5 | P13501 | 1/20 | 0.38 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.37 |
| ▸ | FGF2 | P09038 | 2/20 | 0.36 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531877 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL29535260 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL18079769 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL13321878 | 0.94 | MDK (0.61) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL29371806 | 0.94 | MDK (0.61) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL29501172 | 0.94 | BDNF (0.49) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL29523446 | 0.94 | BDNF (0.49) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL23336378 | 0.91 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL23135897 | 0.89 | BDNF (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL29362404 | 0.89 | MDK (0.44) | MDKBDNFPTNMAPK1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250120999-A1 | SYSTEMS AND METHODS USING SULFATED GLYCOSAMINOGLYCANS (GAGs) AND GAG ANALOGS TO TREAT OR PREVENT MONKEYPOX (MPOX) | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2025-04-17 | — | — | US | claimed |
| WO-2024179533-A1 | AQUEOUS BINDER AND USE THEREOF IN HARD CARBON NEGATIVE ELECTRODE OF SODIUM-ION BATTERY | 郑州大学 | 2024-09-06 | — | — | WO | claimed |
| CN-118580804-A | Water-based binder and application thereof in hard carbon negative electrode of sodium ion battery | 郑州大学 | 2024-09-03 | — | — | CN | claimed |
| WO-2024044398-A1 | SYSTEMS AND METHODS USING SULFATED GLYCOSAMINOGLYCANS (GAGS) AND GAG ANALOGS TO TREAT OR PREVENT MONKEYPOX (MPOX) | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2024-02-29 | — | — | WO | claimed |
| CN-114045278-B | Chondroitin sulfate B, coding gene thereof and construction method thereof | 集美大学 | 2023-11-24 | — | — | CN | claimed |
| CN-116969800-A | Organic fertilizer for soil remediation and preparation method thereof | 广州致高环保新材料科技有限公司 | 2023-10-31 | — | — | CN | claimed |
| US-20230026971-A1 | EXTRACELLULAR MATRIX STRUCTURES | AZIYO MED, LLC (US) | 2023-01-26 | — | — | US | claimed |
| US-11458099-B2 | Inhalable antimicrobial particles and methods of making the same | THE PENN STATE RESEARCH FOUNDATION (US) | 2022-10-04 | — | — | US | claimed |
| CN-114200094-A | Quantitative detection method for chondroitin sulfate polysaccharide content in fermentation liquor | 中化健康产业发展有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-117571860-B | Qualitative and quantitative analysis method for heparinoid component | SOOCHOW UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12636309-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | ADORA ANIMAL HEALTH CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-12636308-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | ADORA ANIMAL HEALTH CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| CN-122031445-A | External pharmaceutical composition containing loxoprofen | 第一三共健康事业株式会社 | 2026-05-15 | — | — | CN | disclosed |
| US-20260124237-A1 | CARTILAGE REGENERATION COMPOSITION | KOBAYASHI PHARMACEUTICAL CO LTD (JP) | 2026-05-07 | — | — | US | disclosed |
| US-20220023503-A9 | Extracellular Matrix Tissue Prostheses | ELUTIA INC. (F/K/A AZIYO BIOLOGICS, INC.) | 2022-01-27 | — | — | US | disclosed |
| EP-3943501-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | Halozyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2022015794-A1 | METHODS FOR SYNTHESIZING NON-ANTICOAGULANT HEPARAN SULFATE | OPTIMVIA, LLC (US) | 2022-01-20 | — | — | WO | disclosed |
| US-20220010344-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | GINKGO BIOWORKS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2021007429-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | OPTIMVIA LLC (US) | 2021-01-14 | — | — | WO | disclosed |
| WO-2006008173-A2 | PHARMACEUTICAL FORMULATIONS FOR INHALATION | GLAXO GROUP LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636308-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | FUT6, CD44, CSGALNACT1 | MDK 3439/4885BDNF 620/4885PTN 718/4885 |
| US-20220010344-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | CSGALNACT1, NANS, STS | MDK 4814/4885BDNF 4749/4885PTN 887/4885 |
| US-20260124237-A1 | CARTILAGE REGENERATION COMPOSITION | CSGALNACT1, CD44, HCAR1 | MDK 2252/4885BDNF 495/4885PTN 1390/4885 |
| US-12636309-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | CD44, FUT8, FUT6 | MDK 2659/4885BDNF 1092/4885PTN 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.